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Approximately 5–10% of breast cancer is due to inherited predis-
position (Miki et al, 1994). Germ-line mutations in the two identi-
fied susceptibility genes, BRCA1 (Miki et al, 1994) and BRCA2
(Wooster et al, 1994; Tavtigian et al, 1996) are responsible for a
large proportion of hereditary breast cancer (Szabo and King,
1997). Both BRCA1 and  BRCA2 are considered as classical
tumour suppressor genes and therefore inactivation of both alleles
is required for cancer initiation. Although no sequence homology
has been found between BRCA1 and BRCA2, they share many
functional properties (reviewed in Welcsh et al, 2000). 
Almost all the tumours from germ-line BRCA1 and BRCA2 muta-
tion carriers show loss of heterozygosity (LOH) or AI at the corre-
sponding loci (Smith et al, 1992; Neuhausen and Marshall, 1994;
Collins et al, 1995; Gudmunsson et al, 1995; Staff et al, 2000),
which is in accordance with the lost tumour suppressor function.
Due to several functional parallels between BRCA1 and BRCA2, we
studied the possible somatic aberrations of BRCA1 by AI and FISH
in breast cancer tumours from germ-line BRCA2 mutation carriers,
and vice versa. The possible concomitant somatic aberrations of the
BRCA1 and BRCA2 genes were also studied in 14 sporadic breast
cancer samples by FISH. We have previously shown (Staff et al,
2000) that unlike in hereditary BRCA1/2 tumours, the allelic imbal-
ance at BRCA1/2 loci is almost always a result of a physical dele-
tion in sporadic tumours. Therefore, physical deletion of the BRCA
genes detected by FISH reflects the allelic imbalance of the
BRCA1/2 loci in sporadic tumours (Staff et al, 2000). 
MATERIALS AND METHODS 
Patients and tumour samples 
17 primary breast cancer tumours from germ-line BRCA1 muta-
tion carriers and 8 primary breast tumours from germ-line BRCA2
mutation carriers were derived from the Department of Oncology,
University of Lund. 14 primary sporadic breast cancer tumours
were obtained from Tampere University Hospital. The tumour
samples were snap-frozen and stored at –70˚C until used for AI
and FISH analyses. 
Genomic DNA was extracted from available blood samples of
the 13 BRCA1 and 6 BRCA2 germ-line mutation carriers by stan-
dard methods. One BRCA1 patient had 2 separate tumours (Ca
8571 and Ca 13996; Table 1), which were both analysed. BRCA1
patients with tumours Ca 14090 and Ca 14007 (Table 1) were rela-
tives, but none of the other BRCA1 patients were directly related.
One BRCA2 patient had also 2 separate tumours (Ca 11 900 and 14
486; Table 2). BRCA2 patients with tumours Ca 7936 and Ca
11506 were from the same family, similarly as patients with
tumours Ca 11787 and Ca 13816 (Table 2). BRCA1 and BRCA2
mutation analyses have been described previously (Johansson 
et al, 1996; Håkansson et al, 1997; Tables 1 and 2). 
PCR microsatellite analysis 
Polymerase chain reaction (PCR) was used to detect AI at poly-
morphic microsatellite markers by comparing the allelic patterns
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Table 1 Copy number aberrations of BRCA2 by FISH and AI in 17 breast cancers from germ-line BRCA1 mutation carriers 
Tumour BRCA1 Result of the AI at the AI at the DNA Mean copy Mean copy Mean copy Interpretation 
mutation BRCA1 mutation BRCA1 BRCA2 Indexc number/cell number/cell of number of the BRCA2 copy 
locusa locusb of BRCA2 13q reference ratio (BRCA2/ number by FISHd
(±SEM) probe (±SEM) 13q reference probe)
Ca 12 421 2594delC Ile845Stop NA NA 1.56 3.84 (0.11) 2.55 (0.09) 1.51 3:4 BRCA2 gain 
Ca 11 808 3829delT Leu1263Stop Yes Yes 1.0 1.18 (0.09) 1.20 (0.09) 0.98 Monosomy of 13q 
Ca 09 252 2594delC Ile845Stop Yes Yes 1.8 2.47 (0.11) 3.45 (0.10) 0.72 3:2 BRCA2 deletion 
Ca 14 007 3172ins5 Thr1025Stop Yes Yes 1.53 1.43 (0.08) 2.71 (0.10) 0.53 3:2 BRCA2 deletion 
Ca 10 581 1806C→ T Gln563Stop Yes NI 1.73 2.17 (0.12) 3.66 (0.16) 0.59 4:2 BRCA2 deletion 
Ca 12 224 1806C→ T Gln563Stop Yes Yes 1.52 2.10 (0.10) 2.50 (0.11) 0.84 Large deletion at 13qe.f
Ca 14 510 300T→ G Cys61Gly Yes Yes 2.46 2.43 (0.17) 2.53 (0.15) 0.96 Large 13q deletionf
Ca 10 360 3172ins5 Thr1025Stop Yes Yes 1.7 1.80 (0.09) 1.94 (0.07) 0.98 Large 13q deletionf
Ca 13 812 4808C→ G Glu1115Stop Yes NI 1.87 1.82 (0.08) 1.98 (0.08) 0.92 Large 13q deletionf
Ca 13 714 5382insC Glu1829Stop Yes No 2.48 3.30 (0.18) 3.06 (0.09) 1.08 Large 13q deletionf
Ca 13 996 1806C→ T Gln563Stop Yes Yes 1.11 1.84 (0.09) 2.24 (0.10) 0.82 No relative copy number change 
Ca 14 970 2594delC Ile845Stop Yes Yes 1.00 2.26 (0.11) 2.21 (0.09) 1.02 No relative copy number change 
Ca 11 394 1177G→ A Trp353Stop NA NA 1.0 2.40 (0.14) 2.95 (0.14) 0.81 No relative copy number change 
Ca 08 822 1201del11 Ser361Stop Yes NA 1.69 3.16 (0.16) 3.35 (0.11) 0.94 No relative copy number change 
Ca 10 697 Linkage + Yes NA 1.51 3.11 (0.17) 3.18 (0.15) 0.98 No relative copy number change 
Ca 14 090 3172ins5 Thr1025Stop Yes No 1.00 2.08 (0.10) 2.19 (0.08) 0.95 No relative copy number change 
Ca 08 571 1806C→ T Gln563Stop Yes No NA 3.20 (0.19) 3.35 (0.17) 0.96 No relative copy number change 
Copy numbers represent the mean of at least 50 nuclei counted from each sample. (NA = Not available, NI = Not informative) aPreviously published (Staff et al, 2000). bAllelic imbalance was analysed using
microsatellite markers 13S267 and 13S260. AI was stated if at least one of the markers used indicated imbalance (compared to normal DNA) of more than 25% between the alleles in tumour sample. cDNA index by
DNA flow cytometry. dDeletion was defined if the copy number ratio was 0,80 or less. Gain was defined if the copy number ratio was 1.30 or more. e3:2 BRCA2 deletion in a subpopulation. fWhen DNA-index was used
as copy number reference, the copy number ratios indicated a large deletion in 13q spanning both BRCA2 and ETB genes. When 13q probe (ETB) was used as a reference probe, no BRCA2 gene copy number
change was revealed. 
Table 2 Copy number aberrations of BRCA1 by FISH and AI in 8 breast cancers from germ-line BRCA2 mutation carriers 
Tumour BRCA2 Result of AI at the AI at the DNA Mean copy Mean copy Mean copy Interpretation of the BRCA1 
mutation the BRCA2 BR TCA2 BRCA1 indexc number/cell of number/cell of number ratio  copy number by FISHd
mutation locusa locusb BRCA1 (±SEM) chr 17 centromere (BRCA1/ chr 17 cen)
(±SEM)
Ca 11 900 2024del5 Ser599Stop Yes Yes 1.89 2.27 (0.15) 5.44(0.27) 0.42 5:2 BRCA1 deletion 
Ca 10 588 4486delG Val1447Stop NA NA 1.07 1.10 (0.04) 2.0 (0.07) 0.55 2:1 BRCA1 deletion 
Ca 13 816 3058A→ T Lys944Stop Yes Yes 1.00 1.18 (0.05) 1.0 (0.00) 1.18 Monosomy of chromosome 17 
Ca 14 486 2024del5 Ser599Stop Yes Yes 1.87 2.14 (0.11) 4.42(0.20) 0.48 4:2 BRCA1 deletion 
Ca 07 936 6293C→ G Ser2022Stop No Yes NA 2.19 (0.13) 2.34(0.14) 0.94 No relative copy number change 
Ca 11 721 5445del5 Tyr1739Stop NA NA 1.00 3.04 (0.18) 3.68(0.13) 0.83 No relative copy number change 
Ca 11 787 3058A→ T Lys944Stop Yes Yes 1.94 4.08 (0.12) 3.92(0.09) 1.04 No relative copy number change 
Ca 11 506 6293C→ G Ser2022Stop Yes No 1.96 2.77 (0.12) 2.27 (0.07) 1.22 No relative copy number change 
Copy numbers represent the mean of at least 50 nuclei counted from each sample. (NA = Not available). aPreviously published (Staff et al, 2000). bAllelic imbalance was analysed using microsatellite markers
17S1322 and 17S855. AI was stated if at least one of the markers used indicated imbalance (compared to normal DNA) of more than 25% between the alleles in tumour sample. cDNA index by DNA flow cytometry.
dDeletion was defined if the copy number ratio was 0.80 or less. Gain was defined if the copy number ratio was 1.30 or more. of tumour and blood DNA. Two BRCA1 intragenic markers
(D17S855 and D17S1322) (Albertsen et al, 1994) and 2 markers
physically linked to BRCA2 (D13S260 and D13S267) (Wooster 
et al, 1994) were analysed using primers with published sequence
(Gyapay et al, 1994) (Research Genetics, Huntsville, AL, USA).
The PCR reactions were carried out as previously described (Staff
et al, 2000). 1 µ l of the PCR product was analysed by capillary
electrophoresis using ABI PRISM™310 Genetic Analyser and
GeneScan 2.1 Software according to the manufacturer’s instruc-
tions (Perkin-Elmer). For the informative heterozygous markers,
the AI was determined by calculating ratio of the alleles (L) as
previously described (Staff et al, 2000). If L < 0.75 or L > 1.33,
then one of the alleles has decreased more than 25% resulting in
AI, as previously defined (Kerangueven et al, 1997). 
FISH analyses 
FISH analyses were performed using gene-specific PAC probes
for BRCA1 (PAC 103014) and BRCA2 (PAC 92M18) genes. The
specificity of these clones has previously been confirmed (Staff 
et al, 2000). Chromosome 17 centromere probe (p17H8) was used
as a copy number reference for BRCA1. For BRCA2, a PAC probe
specific for the ETB gene (at 13q22) was used as a reference,
because specific centromere probe for chromosome 13 is not avail-
able. The hybridization efficiency of the probes was tested in a
non-malignant breast sample. Hybridization and detection were
performed as previously described (Tanner et al, 1998; Staff et al,
2000). Hybridization signals from 50–100 nuclei were scored to
assess the copy number of the BRCA1 and BRCA2 genes. Deletion
of the BRCA genes was defined as an average ratio ≤ 0.80 of
BRCA1/2 signals relative to chromosome 17 centromere signals or
ETB signals, respectively. Gain was defined as an average ratio of
≥ 1.30. Digital images were taken with a Hamamatsu 9585 camera
(Hamamatsu, Hamamatsu City, Japan) operated via ISIS image
analysis software (MetaSystems, Altslussheim, Germany). 
RESULTS 
BRCA1 and BRCA2 tumours 
11 out of 13 BRCA1 mutation carriers with available blood
samples were informative, i.e. they were heterozygous for at least
one of the two BRCA2 markers. AI at BRCA2 was found in 8 of the
11 (73%) informative cases (Figure 1, Table 1). All the 17 BRCA1
tumours were analysed for the BRCA2 gene copy number by FISH.
3 tumours showed a clear physical interstitial deletion of the
BRCA2 gene when BRCA2 signals were compared to the reference
gene signal counts (ETB gene at 13q22) (Figure 1, Table 1). If the
overall ploidy level (= DNA index by flow cytometry) was used as
a BRCA2 copy number reference, 6 additional tumours showed a
loss of BRCA2. This suggests a large deletion at 13q comprising
both  ETB and  BRCA2 genes in all but one of these tumours
Somatic genetic changes in BRCA1/2 breast cancer 1203
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Figure 1 Examples of the assessment of allelic imbalance (AI) by automated DNA sequencer and two-colour FISH of BRCA1, chromosome 17 centromere,
BRCA2 and ETB (13q reference probe). The AI and FISH analyses of the same tumour are presented next to each other so that AI analysis is shown in the left.
The fragment analysis of PCR products is shown from tumour DNA (top rows) and from matched blood DNA (bottom rows). Size of PCR products (in base
pairs) is shown on the X-axis, and the peak heights in fluorescence units are shown on the Y-axis. The alleles in the normal DNA and the corresponding peaks
in the tumour DNA are shown in grey. The corresponding allele peak areas in informative tumours are presented in boxes next to the peaks. In FISH images, 
the probes are visualised in green and red colours (fluorescein and Texas Red, respectively). The probes are marked with the corresponding colour in each
panel. The nuclei were counterstained with DAPI (blue). The case numbers are marked in each panel with white colour texture. (A) Tumour 11 900 from 
germ-line BRCA2 mutation carrier showing AI at the BRCA1 locus with marker D17S1322 and physical deletion of BRCA1 by FISH. (B) Tumour 11 787 
from germ-line BRCA2 mutation carrier demonstrating AI at the BRCA1 locus with marker D17S855 and no relative BRCA1 gene copy number change by FISH.
(C) Tumour 09 252 from germ-line BRCA1 mutation carrier showing AI at the BRCA2 locus with marker D13S260 and physical deletion of BRCA2 by FISH. 
(D) Tumour 10 360 from germ-line BRCA1 mutation carrier showing AI at the BRCA2 locus with marker D13S260 and no BRCA2 gene copy number change
relative to 13q reference probe by FISH (Ca 12 224). In Ca 12 224, ETB copy number loss was present
only in approximately 50% of the tumour cells (ETB gene copy
number average 2.50) suggesting an interstitial deletion of BRCA2
gene in a subpopulation. Thus, loss of at least one copy of the
BRCA2 gene was present in 53% (9/17) of the BRCA1 tumours. 
All but one of the informative BRCA1 tumours showing change
in the relative BRCA2 gene copy number showed also AI at the
BRCA2 locus (Figure 1, Table 1). 7 out of 17 (41%) of the BRCA1
tumours did not reveal any relative BRCA2 copy number change,
although 2 of them (i.e. 2 out of 4 informative cases) showed AI of
BRCA2 (Table 1). One tumour (1/17; 6%) showed a copy number
gain of the BRCA2 gene but this tumour was not available for AI
analysis (Table 1). 
5 of the available 6 BRCA2 tumours (83%) showed AI at the
BRCA1 locus (Figure 1, Table 2). All the tumours were also
analysed by FISH, and 4 of them (4/8; 50%) showed a physical
deletion of the BRCA1 gene (Figure 1, Table 2). All the informa-
tive cases with deletion of BRCA1 showed AI at the BRCA1 locus
(Figure 1, Table 2). 4 of 8 (50%) tumours revealed no relative
BRCA1 copy number change, yet 2 of these cases showed AI of
BRCA1 (Figure 1, Table 2). 
Sporadic breast tumours 
14 unselected primary sporadic breast cancers were analysed for
both BRCA1 and BRCA2 gene copy number changes by FISH.
Physical deletion of BRCA1 was detected in 6 cases (6/14, 43%).
Loss of BRCA2 was present in 7 cases (7/14, 50%). The concomi-
tant deletion of both the BRCA genes was detected by FISH in only
4 tumour samples (4/14, 29%). FISH data of the sporadic tumours
are summarised in Table 3. 
DISCUSSION 
In the present study, we have studied BRCA1 copy number
changes and AI in BRCA2 mutation tumours and vice versa. Only
one study has been published previously on concomitant allelic
loss of BRCA1 and BRCA2 in hereditary breast cancer. It involved
7 BRCA1-linked breast cancers, which showed combined LOH at
BRCA1/2 loci at high level (Kelsell et al, 1996). Unfortunately,
due to low incidence of BRCA mutation tumours, studies of
BRCA1/2 tumour features have been complicated by small sample
size. Nevertheless, we were here able to study a reasonable
number of BRCA1 cases and extend the study to concern also
BRCA2 tumours. Our results showed a high prevalence (73% in
BRCA1 tumours, Table 1;67% in BRCA2 tumours, Table 2) of
combined AI of BRCA genes in both BRCA1/2 tumours. 
Taken together both BRCA1 and BRCA2 tumours available for
AI analyses, concomitant allelic loss were detected in 12 (71%)
out of 17 cases. In contrast, the set of sporadic breast cancer
showed loss of both BRCA genes by FISH only in 4 (29%) out of
14 tumours (Table 3). We have shown previously that AI of both
BRCA genes in sporadic breast cancer results mainly from phys-
ical deletion of the BRCA genes, which is detectable by FISH.
Therefore, we think that it is possible to compare hereditary AI
data with FISH data from sporadic tumours. When the frequency
of concomitant loss of BRCA1/2 genes was statistically compared
between hereditary and sporadic tumours, a significant difference
between these two groups was found (Pearson χ 2 = 5.43; P <
0.02). Sporadic breast cancers reported in literature also have
shown combined LOH of BRCA1 and BRCA2 at lower frequency
(47% in Kelsell et al, 1996; 32% in Silva et al, 1999) than in the
hereditary tumours analysed here. In sporadic cancers, LOH/AI
has frequently been seen at either BRCA1 or BRCA2 locus, at
17q21 (24–38%) or 13q12–13 (18–63%), respectively (Nagai et
al, 1994; Hamann et al, 1996; van den Berg et al, 1996;
Niederacher et al, 1997; Phelan et al, 1998). However, controversy
exists whether AI/LOH only at the single BRCA locus is clinically
significant in sporadic tumours (Beckmann et al, 1996, Bieche 
et al, 1997; Silva et al, 1999). 
Our results imply that combined AI at the BRCA loci might
reflect a common pathway in tumour progression of hereditary
breast cancers. In contrast, BRCA1/2 were concomitantly affected
only in a minority of sporadic breast cancers, which further
suggests that concomitant somatic loss of BRCA genes is a typical
feature of hereditary and not sporadic breast tumours. 
Comparison of FISH and AI data makes it possible to distin-
guish whether allelic imbalance is due to a physical deletion or
whether it is due to other genetic mechanisms. In general, BRCA
1204 S Staff et al 
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Table 3 Summary of FISH analyses of both BRCA1 and BRCA2 genes in 14 sporadic breast cancers 
Sporadic Interpretation of BRCA1 Interpretation of BRCA2 
cases copy number by FISH* copy number by FISH* 
Case 1** 4:2 BRCA1 deletion 3:2 BRCA2 deletion 
Case 2** 4:2 BRCA1 deletion 3:2 BRCA2 deletion 
Case 3 No relative BRCA1 copy number change Monosomy of chromosome 13 
Case 4 No relative BRCA1 copy number change No relative BRCA2 copy number change 
Case 5** Monosomy of chromosome 17 Monosomy of chromosome 13 
Case 6 No relative BRCA1 copy number change 3:2 BRCA2 deletion 
Case 7** 4:2 BRCA1 deletion 5:3 BRCA2 deletion 
Case 8 No relative BRCA1 copy number change 3:2 BRCA2 deletion 
Case 9 No relative BRCA1 copy number change No relative BRCA2 copy number change 
Case 10 2:1 BRCA1 deletion No relative BRCA2 copy number change 
Case 11 No relative BRCA1 copy number change No relative BRCA2 copy number change 
Case 12 2:1 BRCA1 deletion No relative BRCA2 copy number change 
Case 13 No relative BRCA1 copy number change No relative BRCA2 copy number change 
Case 14 No relative BRCA1 copy number change No relative BRCA2 copy number change 
*Deletion was defined if the copy number ratio (BRCA1 gene copy number signals/chromosome 17 centromere signals or BRCA2
gene copy number signals/ETB gene copy number signals) was 0.80 or less. **Concomitant loss of BRCA1 and BRCA2. copy number changes and AI were in good agreement. However,
in some cases AI was detected in the absence of actual gene copy
number loss suggesting that deletion does not always explain AI.
In theory, illegitimate homologus mitotic recombination could
promote AI without any actual gene copy number losses, which
are detected by FISH. However, whether these findings are truly
linked to BRCA mutation tumours, requires further studies. 
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